FDA panel supports use of Alkermes' Vivitrol to treat opioid dependence
This article was originally published in Scrip
Executive Summary
The US FDA's psychopharmacologic drugs advisory committee has given overwhelming support, voting 12-1, for the supplemental approval of Alkermes' Vivitrol – a proprietary once-monthly injectable formulation of the generic oral drug naltrexone – to treat opioid dependence.